Skin cancer is no longer a marginal or seasonal concern. It is the most prevalent form of cancer in the United States, and its incidence continues to rise year after year. Yet the infrastructure designed to detect it early has failed to scale with the growing need. Today, roughly 30 million Americans are estimated to be living with undiagnosed skin cancer, not because symptoms are hidden, but because access to timely dermatological care has become increasingly limited. The math alone explains the problem. With only around 11,000 dermatologists serving a population of more than 330 million people, specialist capacity has been stretched to a breaking point. For individuals who notice a suspicious mark on their skin, the path to clarity is often long and uncertain. Six, nine, even twelve months of waiting for an appointment is common. By the time a diagnosis is confirmed, what could have been a simple intervention may have progressed into something far more serious. Stephen Bonner, CEO of SkinIO, describes the situation plainly, “Skin cancer is one of the few cancers where early detection almost completely changes the outcome. The tragedy is that we already know how to find it early—we just haven’t had a system that makes early detection accessible to everyone.”

Rethinking How Skin Cancer is Diagnosed

SkinIO was built to change that equation. Rather than asking patients to navigate long waitlists and geographic barriers, the company has created a technology-enabled pathway that moves detection forward in time, closer to the moment a concern first arises. At its foundation is a mobile application that allows individuals to complete a guided, full-body skin scan using a smartphone or tablet, supported by patented artificial intelligence and reviewed by board-certified dermatologists.

The experience is designed to be comprehensive, not reactive. Instead of focusing on a single mole or lesion, the app captures high-quality images of 13 regions across the body, creating a complete visual record of the patient’s skin. The AI embedded in the platform guides users through the process, ensuring correct lighting, distance, and positioning so that each image meets clinical standards. “The goal was never to replace dermatologists,” Bonner explains. “The goal was to make sure their time is used where it matters most, and that people don’t fall through the cracks simply because they couldn’t get an appointment.”

Once a scan is completed, SkinIO’s technology takes over by establishing a personalized baseline, by mathematically modeling what is normal for that individual’s skin. From there, it identifies statistically significant outliers—lesions that differ in ways associated with potential malignancy. Everyday variations such as freckles, tattoos, or scars are filtered out, allowing the technology to focus only on changes that matter medically. Those AI-flagged images are then reviewed by dermatologists from SkinIO’s national panel. The physician does not rely on automation alone. Instead, clinical judgment and experience are layered on top of the technology’s findings to determine the appropriate next step. The results are delivered to the patient in clear terms. For roughly two-thirds of users, there is no immediate cause for concern, and their scans become a baseline for future comparison. About one-fifth are advised to monitor certain areas over time. For the remaining group—typically eight to ten percent—SkinIO identifies a need for in-clinic evaluation and acts immediately to connect the patient to care. “In the traditional system, finding a problem often means starting a new search for a dermatologist,” Bonner says. “We eliminate that delay by closing the loop. If someone needs to be seen, we already know where and how to get them there.”

Closing the Gap Between Detection and Care

One of SkinIO’s most critical differentiators is its ability to convert early detection into timely treatment. Through a network of more than 600 dermatologists across the United States, the company ensures that patients flagged as high risk are seen in clinic, often within three weeks. That speed is not incremental—it is transformative. Skin cancer is highly curable when caught early. Melanoma, in particular, has dramatically different outcomes depending on the stage at which it is diagnosed. By compressing the timeline from concern to confirmation, SkinIO shifts the odds decisively in the patient’s favor. Bonner underscores the impact, “If we were scanning people regularly and acting quickly on what we find, late-stage skin cancer would become incredibly rare. The disease hasn’t changed—the system has.”

Clinical credibility has been central to SkinIO’s development. Independent studies conducted with leading academic institutions, including Stanford and Northwestern dermatology programs, have shown the platform achieving accuracy rates approaching 95 percent. In comparison, visual exams performed in clinic by even highly trained dermatologists typically reach lower accuracy levels. Beyond performance, SkinIO also addresses the practical realities of healthcare access. A full scan costs $239, often less than the total cost of an in-person dermatology visit once travel, missed work, and follow-up appointments are considered. More importantly, it removes hesitation. Patients no longer have to decide whether a concern is “serious enough” to justify months of waiting.

Trust, however, extends beyond clinical outcomes. SkinIO operates in an area where privacy is paramount. Images are encrypted, never stored on personal devices, and remain fully under the patient’s control. The platform is HIPAA compliant and nearing SOC 2 certification, reinforcing its commitment to enterprise-grade data security.

“People are trusting us with something deeply personal,” Bonner notes. “That trust only exists if patients know their data is protected and that they control who sees it.”

A Life Saved Through Early Detection

The real-world impact of SkinIO’s approach is perhaps best illustrated through its employer deployments. One of the company’s largest partnerships is with United Airlines, where SkinIO offers on-site scanning at major airport hubs for flight crews and ground staff. During one such deployment in San Francisco, an employee returned to the scanning station with a message that left a lasting impression. A year earlier, he had come in worried about a small spot on his arm, which turned out to be harmless. What SkinIO’s scan uncovered instead was a large melanoma on his back—something he had never seen or felt. The company connected him to care within weeks. After treatment, he was cured. “That story stays with us,” Bonner says. “Not because it’s rare, but because it shows what happens when you look at the whole picture instead of just the obvious concern.”

SkinIO remains focused exclusively on skin cancer today, but its technology hints at broader possibilities. Pharmaceutical and research organizations have already explored adapting the platform for dermatology clinical trials, where patient recruitment and long-term compliance are persistent challenges. Remote, AI-supported scanning could significantly reduce dropout rates and improve trial outcomes. For now, the company’s immediate priority is scale. SkinIO continues to expand employer partnerships, raise awareness within the healthcare ecosystem, and prepare for a direct-to-consumer offering. While the technology is ready, leadership is deliberate about timing, recognizing that consumer trust must be earned through education and consistency. This need is especially acute in rural America. Nearly 80 percent of U.S. counties have no resident dermatologist. For those populations, SkinIO is not just a convenience—it is often the only realistic pathway to early assessment. Bonner puts it simply: “People shouldn’t have to drive three hours just to find out whether something on their skin matters.”

Changing the Narrative Around Skin Health

Perhaps the most striking contradiction in modern healthcare is how normalized preventive dental care has become, while preventive skin cancer screening remains overlooked. Insurance systems routinely cover biannual dental exams without question, yet skin cancer—despite being more deadly—has not received the same structural support. SkinIO’s work challenges that imbalance. By proving that early detection can be accurate, affordable, and scalable, the company is reframing skin health as a routine part of preventive care rather than a specialist-only concern.

As skin cancer incidence rises among younger populations and awareness continues to grow, SkinIO’s model offers a glimpse of what the future could look like – faster answers, fewer advanced diagnoses, and a healthcare system that intervenes before it is forced to react. “The tools to change outcomes already exist,” Bonner reflects. “What we’re doing is making sure people can actually use them.”